LDN-193189 . dihydrochloride

• GMP format available

LDN-193189 . dihydrochloride is a potent and selective inhibitor of ALK2 and ALK3 (IC₅₀ values of 5 nM and 30 nM, respectively), making it a valuable tool in the study of bone morphogenetic protein (BMP) signaling pathways. This compound is widely used in research for its ability to inhibit SMAD1/5/8 phosphorylation, which is crucial for various cellular processes.

Key features and applications include:

• High Selectivity: Exhibits over 200-fold selectivity for BMP signaling over TGF-β signaling.
• Neural Induction: Promotes the neural induction of human pluripotent stem cells (hPSCs) when used in combination with other inhibitors.
• Stem Cell Research: Facilitates the differentiation of hPSCs into nociceptive sensory neurons and motor neurons.
• Developmental Biology: Used in studies to understand the role of BMP signaling in development and disease.

Relevant disease states include:

• Cancer: LDN-193189 . dihydrochloride has been studied for its potential in inhibiting certain pathways involved in cancer progression.
• Fibrodysplasia Ossificans Progressiva (FOP): FOP is a rare genetic disorder characterized by the abnormal development of bone in muscles, tendons, and other soft tissues. LDN-193189 . dihydrochloride has shown promise in inhibiting the BMP signaling pathway, which is crucial in the pathogenesis of FOP. By targeting ALK2, the compound helps prevent the inappropriate bone formation that occurs in this condition.
• Atherosclerosis: LDN-193189 . dihydrochloride has also been investigated in the context of atherosclerosis, a condition where plaque builds up inside the arteries. In animal models, the compound has been shown to inhibit the development of atheroma and associated vascular inflammation, suggesting it could help in managing cardiovascular diseases.